Raymond James Trust N.A. Has $10.96 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Raymond James Trust N.A. lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,826 shares of the medical research company’s stock after selling 157 shares during the quarter. Raymond James Trust N.A.’s holdings in Thermo Fisher Scientific were worth $10,964,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Beaumont Financial Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock valued at $1,278,000 after acquiring an additional 17 shares in the last quarter. Cedar Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 14.5% in the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 17 shares during the last quarter. Patrick M Sweeney & Associates Inc. grew its position in shares of Thermo Fisher Scientific by 1.8% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company’s stock valued at $570,000 after acquiring an additional 18 shares during the period. Quent Capital LLC raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the 2nd quarter. Quent Capital LLC now owns 1,886 shares of the medical research company’s stock worth $1,043,000 after purchasing an additional 19 shares during the period. Finally, Prentice Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 2.1% in the second quarter. Prentice Wealth Management LLC now owns 913 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Marc N. Casper sold 6,300 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,548,375.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,084 shares of company stock valued at $19,767,092. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Barclays dropped their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. HSBC upped their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Royal Bank of Canada boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $618.94.

Thermo Fisher Scientific Trading Up 0.4 %

NYSE TMO traded up $2.26 on Friday, hitting $606.12. The company’s stock had a trading volume of 777,265 shares, compared to its average volume of 1,530,541. The firm has a market cap of $231.37 billion, a P/E ratio of 38.88, a PEG ratio of 2.81 and a beta of 0.77. The company’s 50-day simple moving average is $574.15 and its 200 day simple moving average is $573.97. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $622.30. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $5.15 earnings per share. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.